| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| 1 | 08-08-2024 | 06-30-2024 | 10-Q | |
| 2 | 05-09-2024 | 03-31-2024 | 10-Q | |
| 3 | 03-14-2024 | 12-31-2023 | 10-K | |
| 4 | 11-13-2023 | 09-30-2023 | 10-Q | |
| 5 | 08-14-2023 | 06-30-2023 | 10-Q |
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Intensity Therapeutics (NASDAQ:INTS) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate...
Benchmark analyst Robert Wasserman reiterates Intensity Therapeutics (NASDAQ:INTS) with a Speculative Buy and maintains $12 ...
Benchmark analyst Robert Wasserman reiterates Intensity Therapeutics (NASDAQ:INTS) with a Speculative Buy and maintains $12 ...
Intensity Therapeutics (NASDAQ:INTS) reported quarterly losses of $(0.34) per share. This is a 12.82 percent increase over loss...
- SEC Filing
Benchmark analyst Robert Wasserman reiterates Intensity Therapeutics (NASDAQ:INTS) with a Speculative Buy and maintains $12 ...
Year-End 2023 Financial ResultsResearch and development expenses were $4.8 million for the year ended December 31, 2023, compar...
